Naproxen Cardio Benefit “Not Large Enough” To Back Vioxx Defense – Lancet
This article was originally published in The Tan Sheet
Executive Summary
Naproxen's perceived cardioprotective benefit demonstrated in studies likely is due to coincidence, according to a recent study published in the Lancet
You may also be interested in...
FDA’s Graham Casts Doubt On Naproxen Cardioprotection, Vioxx Defense
Debate during a three-day panel meeting on the safety of COX-2s and NSAIDs appeared to reach a consensus that naproxen carries little to no cardioprotective benefit
FDA’s Graham Casts Doubt On Naproxen Cardioprotection, Vioxx Defense
Debate during a three-day panel meeting on the safety of COX-2s and NSAIDs appeared to reach a consensus that naproxen carries little to no cardioprotective benefit
FDA’s Graham Casts Doubt On Naproxen Cardioprotection, Vioxx Defense
Debate during a three-day panel meeting on the safety of COX-2s and NSAIDs appeared to reach a consensus that naproxen carries little to no cardioprotective benefit